Intelligent Digital Tools for Screening of Brain Connectivity and Dementia Risk Estimation in People Affected by Mild Cognitive Impairment

Launched by OSLO UNIVERSITY HOSPITAL · Dec 10, 2021

Keywords

ClinConnect Summary

This clinical trial, called the AI-Mind project, is studying how to better identify and assess the risk of dementia in people who have mild cognitive impairment (MCI). The goal is to develop two digital tools powered by artificial intelligence that can help spot problems in brain connectivity and provide personalized reports on dementia risk. This approach aims to improve early diagnosis and intervention, potentially allowing people to stay 'dementia-free' for longer.

To be eligible for this trial, participants should be between 60 and 75 years old and have a diagnosis of mild cognitive impairment, with certain scores on specific cognitive tests (MMSE or MoCA). Individuals with confirmed dementia, severe mental disorders, or significant medical conditions affecting cognition are not eligible. Participants can expect to undergo brain connectivity assessments and receive personalized reports that may lead to new treatment options. This trial is currently recruiting participants, and it seeks to make a significant impact on how we approach dementia care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female aged between 60 and 75 years
• • MCI diagnosis with a MMSE \>= 25
• • or MCI diagnosis with MoCa \>= 17
• Exclusion Criteria:
• • Confirmed dementia
• • History of cerebrovascular disease (i.e. stroke episodes)
• • Alcohol Use Disorder Identification Test (AUDIT) score positive
• • Severe medical disorders associated with cognitive impairment (organ insufficiencies, chronic infections, endocrinological disorders)
• • Severe head trauma with structural brain lesion and/or previous brain surgery;
• • Severe mental disorders; Schizophrenia, known Major depression or bipolar disorder
• • Neuroimaging evidence of other potential causes of cognitive decline (e.g. subdural haematoma, malignancy)
• • History of malignancy \< 5 years;
• • Recent use of psychotropic drugs including AChEI and Memantine (\< 3 months);
• • Participation in trials with experimental drugs.